190 related articles for article (PubMed ID: 8384116)
1. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent.
Fride E; Mechoulam R
Eur J Pharmacol; 1993 Feb; 231(2):313-4. PubMed ID: 8384116
[TBL] [Abstract][Full Text] [Related]
2. Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents.
Crawley JN; Corwin RL; Robinson JK; Felder CC; Devane WA; Axelrod J
Pharmacol Biochem Behav; 1993 Dec; 46(4):967-72. PubMed ID: 7906042
[TBL] [Abstract][Full Text] [Related]
3. Isolation and structure of a brain constituent that binds to the cannabinoid receptor.
Devane WA; Hanus L; Breuer A; Pertwee RG; Stevenson LA; Griffin G; Gibson D; Mandelbaum A; Etinger A; Mechoulam R
Science; 1992 Dec; 258(5090):1946-9. PubMed ID: 1470919
[TBL] [Abstract][Full Text] [Related]
4. Effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis in the rat.
Weidenfeld J; Feldman S; Mechoulam R
Neuroendocrinology; 1994 Feb; 59(2):110-2. PubMed ID: 8127398
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo.
Lichtman AH; Hawkins EG; Griffin G; Cravatt BF
J Pharmacol Exp Ther; 2002 Jul; 302(1):73-9. PubMed ID: 12065702
[TBL] [Abstract][Full Text] [Related]
6. Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase.
Vogel Z; Barg J; Levy R; Saya D; Heldman E; Mechoulam R
J Neurochem; 1993 Jul; 61(1):352-5. PubMed ID: 8515284
[TBL] [Abstract][Full Text] [Related]
7. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction.
Felder CC; Briley EM; Axelrod J; Simpson JT; Mackie K; Devane WA
Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7656-60. PubMed ID: 8395053
[TBL] [Abstract][Full Text] [Related]
8. Effects of anandamide on cannabinoid receptors in rat brain membranes.
Childers SR; Sexton T; Roy MB
Biochem Pharmacol; 1994 Feb; 47(4):711-5. PubMed ID: 8129747
[TBL] [Abstract][Full Text] [Related]
9. Delta9-tetrahydrocannabinol, but not the endogenous cannabinoid receptor ligand anandamide, produces conditioned place avoidance.
Mallet PE; Beninger RJ
Life Sci; 1998; 62(26):2431-9. PubMed ID: 9651110
[TBL] [Abstract][Full Text] [Related]
10. Changes in rat brain cannabinoid binding sites after acute or chronic exposure to their endogenous agonist, anandamide, or to delta 9-tetrahydrocannabinol.
Romero J; García L; Fernández-Ruiz JJ; Cebeira M; Ramos JA
Pharmacol Biochem Behav; 1995 Aug; 51(4):731-7. PubMed ID: 7675852
[TBL] [Abstract][Full Text] [Related]
11. Developmental aspects of anandamide: ontogeny of response and prenatal exposure.
Fride E; Mechoulam R
Psychoneuroendocrinology; 1996 Feb; 21(2):157-72. PubMed ID: 8774060
[TBL] [Abstract][Full Text] [Related]
12. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist.
Deutsch DG; Chin SA
Biochem Pharmacol; 1993 Sep; 46(5):791-6. PubMed ID: 8373432
[TBL] [Abstract][Full Text] [Related]
13. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells.
Mackie K; Devane WA; Hille B
Mol Pharmacol; 1993 Sep; 44(3):498-503. PubMed ID: 8371711
[TBL] [Abstract][Full Text] [Related]
14. Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212-2 and anandamide.
Pertwee RG; Stevenson LA; Griffin G
Br J Pharmacol; 1993 Dec; 110(4):1483-90. PubMed ID: 8306090
[TBL] [Abstract][Full Text] [Related]
15. New dawn of cannabinoid pharmacology.
Devane WA
Trends Pharmacol Sci; 1994 Feb; 15(2):40-1. PubMed ID: 8165721
[No Abstract] [Full Text] [Related]
16. Characterization of anandamide-induced tolerance: comparison to delta 9-THC-induced interactions with dynorphinergic systems.
Welch SP
Drug Alcohol Depend; 1997 Apr; 45(1-2):39-45. PubMed ID: 9179505
[TBL] [Abstract][Full Text] [Related]
17. Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides.
Barg J; Fride E; Hanus L; Levy R; Matus-Leibovitch N; Heldman E; Bayewitch M; Mechoulam R; Vogel Z
Eur J Pharmacol; 1995 Dec; 287(2):145-52. PubMed ID: 8749028
[TBL] [Abstract][Full Text] [Related]
18. delta 9-Tetrahydrocannabinol and anandamide enhance the ability of muscimol to induce catalepsy in the globus pallidus of rats.
Wickens AP; Pertwee RG
Eur J Pharmacol; 1993 Nov; 250(1):205-8. PubMed ID: 8119321
[TBL] [Abstract][Full Text] [Related]
19. Neurobehavioral effects of anandamide and cannabinoid receptor gene expression in mice.
Chakrabarti A; Ekuta JE; Onaivi ES
Brain Res Bull; 1998; 45(1):67-74. PubMed ID: 9434204
[TBL] [Abstract][Full Text] [Related]
20. The endogenous cannabinoid receptor ligand, anandamide, inhibits the motor behavior: role of nigrostriatal dopaminergic neurons.
Romero J; García L; Cebeira M; Zadrozny D; Fernández-Ruiz JJ; Ramos JA
Life Sci; 1995; 56(23-24):2033-40. PubMed ID: 7776829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
